In 2011, Clinical Proteomics converted from a subscription publication to a fully open access journal. The journal's back content can be viewed on SpringerLink.
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. Although it is associated with a low mortality rate, uncontrolled or recurrent Prostate Cancer has an average survival rate of just 3 – 5 years. Selecting appropriate treatment options for men with PCa is critical to ensure that those with low risk disease are not over-treated and do not suffer unnecessarily from treatment side-effects, while those at risk for more aggressive disease are treated effectively at an earlier stage. Clinical decision making for PCa is made complicated by the heterogeneous nature of the disease, which renders current biomarkers and clinical methods for patient stratification and personalised treatment insufficient. A greater appreciation of the complex pathology underlying PCa is required to support biomarker research in this area. Concurrently, the application of high throughput proteomic technologies is likely to facilitate the development of biomarker-driven decision tools to meet current clinical needs. This review provides a comprehensive overview of the complexities of PCa pathology and disease management. Current biomarkers for PCa are described, as is the important role of proteomic technologies in advancing continued biomarker research in this area.
Make a suggestion here
Aims and scope
Clinical Proteomics encompasses all aspects of translational proteomics. Special emphasis will be placed on the application of proteomic technology to all aspects of clinical research and molecular medicine. The journal is committed to rapid scientific review and timely publication of submitted manuscripts.
Dr Daniel W Chan is currently Professor of Pathology, Oncology, Urology, and Radiology at Johns Hopkins Medical Institutions, and Director of the Clinical Chemistry Division, Co-Director at the Pathology Core Laboratory, and Director at the Center for Biomarker Discovery and Translation at the Johns Hopkins University School of Medicine. He has worked extensively on the development and application of proteomic and immunologic techniques in the understanding of cancer. As the author of five books and over 300 articles, Dr Chan has become established as a leading expert in clinical proteomics and cancer research. Dr Chan is an active member of US Human Proteome Organization (USHUPO), American Association for Cancer Research (AACR) and American Association for Clinical Chemistry (AACC).
Guest edited by Vera Ignjavtovic, Allen Everett and Hanno Steen
The Paediatric Proteomics (PediOme) is an initiative of HUPO that aims to advance the use of proteomic techniques to solve major issues in Paediatric medicine.
Proteomics in India
Guest edited by Harsha Gowda and Akhilesh Pandey
This collections features the latest advances in Proteomics research from India.
Glycoproteomics and glycomics
Guest edited by Punit Shah and Hui Zhang
This thematic series publishes both solicited and unsolicited content on the topic of protein glycosylation; one of the most common protein modifications in both normal biological processes and diseases. This series focuses on glycoproteomic or glycomic methods and their clinical applications.
Clinical Proteomics is affiliated with the Human Proteome Organization (HUPO). HUPO is an international scientific organization representing and promoting proteomics through international cooperation and collaborations by fostering the development of new technologies, techniques and training.
- Editorial Board
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
80 days to first decision for reviewed manuscripts only
68 days to first decision for all manuscripts
150 days from submission to acceptance
11 days from acceptance to publication
83 Altmetric mentions